Fox K M, Dargie H J, Deanfield J, Maseri A
Royal Brompton National Heart and Lung Hospital, London.
Br Heart J. 1991 Aug;66(2):151-5. doi: 10.1136/hrt.66.2.151.
To investigate the efficacy of transdermal glyceryl trinitrate given continuously and with a nocturnal nitrate free period.
Double blind placebo controlled study with two parallel limbs.
Multicentre trial.
52 patients randomised to receive either continuous treatment (23 patients) or intermittent treatment with an individually titrated dose (29 patients) for 14 days: both treatments were compared with placebo in a cross-over fashion.
Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate or intermittent transdermal glyceryl trinitrate titrated to give an arbitrary 10 mm Hg drop in systolic blood pressure (mean dose 18.2 mg) given over approximately 16 hours.
Treadmill exercise stress testing and ambulatory monitoring of the ST segment after 14 days' treatment.
After 14 days' intermittent treatment resting supine and standing systolic blood pressure fell by 7.5 mm Hg (95% confidence interval 2.7 to 12.2) and 9.0 mm Hg (95% CI 3.4 to 14.5) respectively (p less than 0.01); resting heart rate was unchanged. Mean heart rate at 1 mm ST segment depression rose by 11.9 beats/min (CI 1.1 to 23.7) (p less than 0.05), mean time to onset of angina increased by 59 seconds (CI 10.8 to 108) (p less than 0.05), and total exercise duration increased by 40 seconds (p less than 0.05). These changes were not seen after continuous treatment. The frequency of ischaemic episodes was not reduced with either regimen nor was the circadian distribution of these episodes altered, in particular nocturnal episodes did not increase during intermittent treatment.
Tolerance to glyceryl trinitrate was avoided by the use of individually titrated doses administered with a nocturnal nitrate free period. There was no evidence of "rebound" on ambulatory monitoring during this treatment.
研究持续给予经皮硝酸甘油并设置夜间无硝酸酯期的疗效。
采用双盲安慰剂对照研究,设两个平行组。
多中心试验。
52例患者随机分为两组,分别接受持续治疗(23例)或个体化滴定剂量的间歇治疗(29例),为期14天:两种治疗均采用交叉方式与安慰剂进行比较。
持续给予每24小时10毫克经皮硝酸甘油,或间歇给予经皮硝酸甘油,滴定至收缩压任意下降10毫米汞柱(平均剂量18.2毫克),给药约16小时。
治疗14天后进行跑步机运动应激试验和动态ST段监测。
间歇治疗14天后,静息仰卧位和站立位收缩压分别下降7.5毫米汞柱(95%置信区间2.7至12.2)和9.0毫米汞柱(95%置信区间3.4至14.5)(p<0.01);静息心率无变化。ST段压低1毫米时的平均心率增加11.9次/分钟(置信区间1.1至23.7)(p<0.05),心绞痛发作的平均时间增加59秒(置信区间10.8至108)(p<0.05),总运动持续时间增加40秒(p<0.05)。持续治疗后未见这些变化。两种治疗方案均未降低缺血发作频率,也未改变这些发作的昼夜分布,尤其是间歇治疗期间夜间发作未增加。
通过使用个体化滴定剂量并设置夜间无硝酸酯期可避免对硝酸甘油产生耐受性。在此治疗期间的动态监测中没有“反跳”的证据。